A Phase 2 interventional study of OTX-TIC low dose Travoprost Intracameral Implant and OTX-TIC high dose Travoprost Intracameral Implant in Open Angle Glaucoma and Ocular Hypertension, sponsored by Ocular Therapeutix, Inc.. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 141st largest by enrollment of the 279 interventional ones that give a count, is one of 13 that started in 2022, is one of 76 in phase 2, and was the 271st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
This is a prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy, and safety of OTX-TIC (travoprost) intracameral implant in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT). Approximately 105 subjects will be enrolled in this study at approximately 20 sites in the US. Subjects will be a randomized to one of three treatment groups OTX-TIC drug product (2 travoprost dose strengths) compared to a single injection of DurystaTM. Non study eyes will be treated with the PGA, if not contraindicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost Intracameral Implant low dose
Drug: OTX-TIC low dose Travoprost Intracameral Implant
Travoprost Intracameral Implant high dose
Drug: OTX-TIC high dose Travoprost Intracameral Implant
Bimatoprost Intracameral Implant 10 µg
Drug: Durysta, Bimatoprost Intracameral Implant 10 µg
OTX-TIC implant is injected into the anterior chamber of the eye.
OTX-TIC implant is injected into the anterior chamber of the eye.
Durysta is injected into the anterior chamber of the eye.
IOP Changes From Baseline in the Study Eye
IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.
Time frame: Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)
| Milestone | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta |
|---|---|---|---|
| Started | 16 | 32 | 34 |
| Completed | 16 | 30 | 32 |
| Not completed | 0 | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.
| Millimeter of Mercury (mmHg) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta |
|---|---|---|---|
| Change from Baseline (8 AM) to Week 2 (8 AM) | -7.69 ± 3.807 | -7.66 ± 4.243 | -7.03 ± 3.567 |
| Change from Baseline (10 AM) to Week 2 (10 AM) | -6.37 ± 3.287 | -7.34 ± 4.786 | -6.21 ± 3.162 |
| Change from Baseline (4 PM) to Week 2 (4 PM) | -5.47 ± 3.507 | -6.23 ± 4.291 | -6.19 ± 3.071 |
| Change from Baseline (8 AM) to Week 6 (8 AM) | -7.81 ± 3.130 | -7.70 ± 3.692 | -7.09 ± 3.762 |
| Change from Baseline (10 AM) to Week 6 (10 AM) | -6.40 ± 3.318 | -7.00 ± 4.049 | -5.97 ± 3.665 |
| Change from Baseline (4 PM) to Week 6 (4 PM) | -5.53 ± 2.682 | -5.81 ± 3.823 | -5.87 ± 3.391 |
| Change from Baseline (8 AM) to Week 12 (8 AM) | 0.68 ± 13.476 | -7.03 ± 3.610 | -6.13 ± 3.799 |
| Change from Baseline (10 AM) to Week 12 (10 AM) | -1.38 ± 9.366 | -6.12 ± 3.729 | -5.58 ± 3.170 |
| Change from Baseline (4 PM) to Week 12 (4 PM) | -1.42 ± 8.149 | -5.38 ± 3.651 | -5.79 ± 2.969 |
Collected over From time of administration of study drug to last visit (up to 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-TIC 5 µg | 0/16 (0%) | 1/16 (6.3%) | 12/16 (75%) |
| OTX-TIC 26 µg | 0/32 (0%) | 6/32 (18.8%) | 20/32 (62.5%) |
| Durysta | 0/34 (0%) | 4/34 (11.8%) | 8/34 (23.5%) |
| Event | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta |
|---|---|---|---|
| Rib FractureInjury, poisoning and procedural complications | 1/16 | 0/32 | 0/34 |
| IritisEye disorders | 0/16 | 1/32 | 0/34 |
| FallInjury, poisoning and procedural complications | 0/16 | 1/32 | 0/34 |
| Electrolyte ImbalanceMetabolism and nutrition disorders | 0/16 | 1/32 | 0/34 |
| Mental Status ChangesPsychiatric disorders | 0/16 | 1/32 | 0/34 |
| Renal ImpairmentRenal and urinary disorders | 0/16 | 1/32 | 0/34 |
| Diabetic FootSkin and subcutaneous tissue disorders | 0/16 | 1/32 | 0/34 |
| Upper Limb FractureInjury, poisoning and procedural complications | 0/16 | 0/32 | 1/34 |
| WoundInjury, poisoning and procedural complications | 0/16 | 0/32 | 1/34 |
| PyuriaInfections and infestations | 0/16 | 0/32 | 1/34 |
| Event | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta |
|---|---|---|---|
| Intraocular Pressure IncreasedInvestigations | 6/16 | 2/32 | 1/34 |
| IritisEye disorders | 3/16 | 7/32 | 1/34 |
| Punctate KeratitisEye disorders | 1/16 | 6/32 | 2/34 |
| Eye PainEye disorders | 3/16 | 4/32 | 0/34 |
| Conjunctival HyperaemiaEye disorders | 1/16 | 5/32 | 0/34 |
| Conjuctival HaemorrhageEye disorders | 2/16 | 1/32 | 2/34 |
| Foreign Body Sensation in EyeEye disorders | 2/16 | 2/32 | 1/34 |
| EpiscleritisEye disorders | 2/16 | 1/32 | 0/34 |
| PhotophobiaEye disorders | 2/16 | 1/32 | 0/34 |
| Eye InflammationEye disorders | 2/16 | 0/32 | 0/34 |
Baseline characteristics will be based on mITT population.
| Age, Categorical(Participants) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 13 | 15 | 36 |
| >=65 years | 8 | 19 | 19 | 46 |
| Age, Continuous(years) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 10.29 | 65.1 ± 8.82 | 64.9 ± 12.8 | 64.3 ± 10.88 |
| Sex: Female, Male(Participants) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| Female | 8 | 15 | 15 | 38 |
| Male | 8 | 17 | 19 | 44 |
| Ethnicity (NIH/OMB)(Participants) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 | 14 |
| Not Hispanic or Latino | 13 | 28 | 27 | 68 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 7 | 6 | 17 |
| White | 12 | 24 | 26 | 62 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | OTX-TIC 5 µg | OTX-TIC 26 µg | Durysta | Total |
|---|---|---|---|---|
| United States | 16 | 32 | 34 | 82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Jan 2024, 22 months.
Results were first posted in Sep 2026, 2 years 7 months after primary completion.
Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 22 months is above that.
Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.